

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>22862-0004US1</b>	Application No. <b>10/575,438</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant <b>Wheeler et al.</b>	
		Filing Date <b>April 11, 2006</b>	Group Art Unit <b>1642</b>

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	5,643,786	07/01/1997	Cohen et al.			
	2	5,788,963	08/04/1998	Murphy et al.			
	3	5,849,589	12/14/1998	Tedder et al.			
	4	5,851,756	12/22/1998	Steinman et al.			
	5	5,994,126	11/30/1999	Steinman et al.			
	6	6,010,905	01/04/2000	Cohen			
	7	6,037,135	03/14/2000	Kubo et al.			
	8	6,077,519	05/20/2000	Storkus et al.			
	9	6,479,286	11/12/2002	Nelson et al.			
	10	6,482,405	11/19/2002	Tahara et al.			
	11	6,514,942	02/04/2003	Ioannides et al.			
	12	6,537,560	03/25/2003	Kawakami et al.			
	13	7,247,480	07/24/2007	Waldmann et al.			
	14	7,338,929	03/04/2008	Debinski et al.			
	15	2004/0072246	04/15/2004	Martin et al.			
	16	2004/0197903	10/07/2004	Pestano			
	17	2004/0203143	10/14/2004	Tjoa et al.			
	18	2005/0059151	03/17/2005	Bosch			
	19	2006/0204509	09/14/2006	Harty et al.			
	20	2007/0098776	05/03/2007	Fikes et al.			
	21	2007/0167375	07/19/2007	Okada et al.			
	22	2008/0107668	05/08/2008	Philip et al.			
	23	2008/0199484	08/21/2008	Yu et al.			
	24	2008/0206286	08/28/2008	Yu			
	25	2008/0311141	12/18/2008	Yu et al.			
	26	2008/0311142	12/18/2008	Yu et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>22862-0004US1</b>	Application No. <b>10/575,438</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Wheeler et al.</b>	
		Filing Date <b>April 11, 2006</b>	Group Art Unit <b>1642</b>

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	27	WO 95/21862	08/17/1995	WIPO				
	28	WO 96/18409	06/20/1996	WIPO				
	29	WO 00/24778	05/04/2000	WIPO				
	30	WO 00/38730	07/06/2000	WIPO				
	31	WO 01/08636	02/08/2001	WIPO				
	32	WO 01/41741	06/14/2001	WIPO				
	33	WO 02/68474	09/06/2002	WIPO				
	34	WO 03/035004	05/01/2003	WIPO				
	35	WO 2005/037995	04/28/2005	WIPO				
	36	WO 2005/079581	09/01/2005	WIPO				
	37	WO 2008/039874	04/03/2008	WIPO				
	38	WO 2008/039969	04/03/2008	WIPO				
	39	WO 2008/039974	04/03/2008	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	40	ABDEL-WAHAB et al., "Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity," Cell. Immunol., 186:63-74 (1998)
	41	AKASAKI et al., "Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model," J. Immunother., 24:106-113 (2001)
	42	AKASAKI et al., "Dendritic cell-based immunotherapy for malignant gliomas," Expert Rev. Neurother., 5:497-508 (2005)
	43	AKASAKI et al., "Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma," J. Immunol., 173:4352-59 (2004)
	44	AKASAKI et al., "T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches," Front. Biosci., 10:2908-21 (2005)
	45	CANDIDO et al., "Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents," Cancer Res., 61:228-236 (2001)
	46	CASEY et al., "Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine," Immunology, 110:105-111 (2003)
	47	DIETZ, "Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia," Croatian Med. J., 42:428-435 (2001)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>22862-0004US1</b>	Application No. <b>10/575,438</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant <b>Wheeler et al.</b>	
		Filing Date <b>April 11, 2006</b>	Group Art Unit <b>1642</b>

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	48	EHTESHAM et al., "Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats," J. Immunother., 26:107-116 (2003)
	49	EHTESHAM et al., "Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials," Cancer Control, 11:192-207 (2004)
	50	GATZA et al., "Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma," J. Immunol., 169:5227-35 (2002)
	51	GEIGER et al., "Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression," Cancer Res., 61:8513-19 (2001)
	52	GILBOA et al., "Immunotherapy of cancer with dendritic-cell-based vaccines," Cancer Immunol. Immunother., 46:82-87 (1998)
	53	HIRSCHMANN-JAX et al., "A distinct 'side population' of cells with high drug efflux capacity in human tumor cells," Proc. Natl. Acad. Sci. USA, 39:14228-33 (2004)
	54	LIU et al., "Cancer vaccines: a novel strategy to sensitize malignant glioma to chemotherapy," Expert Rev. Neurother., 7:1235-37 (2007)
	55	LIU et al., "Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma," Cancer Control, 10:138-147 (2003)
	56	LIU et al., "HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells," Cancer Res., 64:4980-86 (2004)
	57	LIU et al., "Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response," Eur. J. Immunol., 34:1680-87 (2004)
	58	LUPTRAWAN et al., "Dendritic cell immunotherapy for malignant gliomas," Rev. Recent Clin. Trials, 3:10-21 (2008)
	59	MEHTA-DAMANI et al., "Generation of antigen-specific CD4+ T cell lines from naïve precursors," Eur. J. Immunol., 5:1206-11 (1995)
	60	MEHTA-DAMANI et al., "Generation of antigen-specific CD8+ CTLs from naïve precursors," J. Immunol., 153:996-1003 (1994)
	61	MELCHER et al., "Dendritic cells for the immunotherapy of cancer," Clin. Oncol., 14:185-192 (2002)
	62	MI et al., "Induced apoptosis supports spread of adenovirus vectors in tumors," Hum. Gene Ther., 12:1343-52 (2001)
	63	PARMIANI et al., "Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going?" J. Natl. Cancer Inst., 94:805-818 (2002)
	64	RISSOAN et al., "Reciprocal control of T helper cell and dendritic cell differentiation," Science, 283:1183-86 (1999)
	65	SONG et al., "Strategies to improve dendritic cell-based immunotherapy against cancer," Yonsei Med. J., 45(Suppl):48-52 (2004)
	66	STEINBRINK et al., "CD4+ and CD8+ anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity," Blood, 99:2468-76 (2002)
	67	TAKAGI et al., "Anti-tumor effects of dendritic and tumor cell fusions are not dependent on expression of MHC class I and II by dendritic cells," Cancer Lett., 213:49-55 (2004)
	68	WHEELER et al., "Cellular immunity in the treatment of brain tumors," Clin. Neurosurg., 51:132-139 (2004)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>22862-0004US1</b>	Application No. <b>10/575,438</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Wheeler et al.</b>	
		Filing Date <b>April 11, 2006</b>	Group Art Unit <b>1642</b>

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	69	YAMAZAKI et al., "Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells," J. Exp. Med., 198:235-247 (2003)
	70	YOUNG et al., "Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells," J. Exp. Med., 171:1315-32 (1990)
	71	YU et al., "Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma," Cancer Res., 64:4973-79 (2004)
	72	ZITVOGEL et al., "Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell-1 associated cytokines," J. Exp. Med., 183:87-97 (1996)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	